Viatris Inc. vs Amneal Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown

Viatris vs Amneal: A Decade of Gross Profit Trends

__timestampAmneal Pharmaceuticals, Inc.Viatris Inc.
Wednesday, January 1, 20144496340003669400000
Thursday, January 1, 20154992260004382200000
Friday, January 1, 20165974550004998500000
Sunday, January 1, 20175261780004976200000
Monday, January 1, 20187164030004572000000
Tuesday, January 1, 20193529970004444200000
Wednesday, January 1, 20206283930003796700000
Friday, January 1, 20217689730005575500000
Saturday, January 1, 20227847080006497000000
Sunday, January 1, 20238205650006438600000
Loading chart...

Cracking the code

A Tale of Two Pharmaceutical Giants: Viatris Inc. vs Amneal Pharmaceuticals, Inc.

In the competitive landscape of pharmaceuticals, Viatris Inc. and Amneal Pharmaceuticals, Inc. have showcased distinct trajectories in gross profit performance over the past decade. From 2014 to 2023, Viatris Inc. consistently outperformed Amneal, with its gross profit peaking at approximately $6.5 billion in 2022, marking a 77% increase from 2014. In contrast, Amneal's growth was more modest, with a peak gross profit of around $820 million in 2023, reflecting an 82% rise since 2014.

Key Insights

  • Viatris Inc.: Demonstrated robust growth, particularly in 2022, with a 14% increase from the previous year.
  • Amneal Pharmaceuticals, Inc.: Despite a slower start, it achieved a significant 132% growth from its lowest point in 2019.

These trends highlight the dynamic nature of the pharmaceutical industry, where strategic decisions and market conditions can lead to varying financial outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025